NCT07230249Not yet recruiting
Telegram Messenger Support for Smoking Cessation After Heart Attack
Effect of a Behavioral Intervention Delivered Via Telegram Messenger on Smoking Cessation in Patients After Myocardial Infarction: The TELEGRAM-MI Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI). Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either: * INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support. * CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content. The primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics. This study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- First submitted
- 13 Nov 2025
- Start date
- 27 Jul 2026
- Primary completion date
- 27 Apr 2027
- Lead sponsor
- ITMO University
- Diseases
- Coronary artery disease
- NCT number
- NCT07230249
What you commit to
- Study type: Interventional
- Planned participants: 142
- From 27 Jul 2026 to the primary completion date, 27 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Smoking cessation more than 1 month prior to the index MI hospitalization.
Other illness
- Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual/hearing impairment, inability to read or respond to messages).
- Comorbid condition with a life expectancy of less than 1 year.
- Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.
Other
- Inability to read and understand the Russian language fluently.
- Unwillingness or inability to provide contact details for a close relative for outcome verification.
Who the study is looking for
- Willing and able to provide written informed consent.
- Age 18 years or older.
- Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).
- Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.
- Regular user of the Telegram messenger application (app installed on a personal smartphone).
- Possession of a smartphone with internet access and a valid phone number.
- Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ulyanovsk Regional Clinical Hospital Coordinator of this site? Confirm its status | Ulyanovsk | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.